Liu Kai, Zhou Rui, Wang Bin, Mi Man-Tian
From the Research Center for Nutrition and Food Safety, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing Medical Nutrition Research Center, Chongqing, PR China.
Am J Clin Nutr. 2014 Jun;99(6):1510-9. doi: 10.3945/ajcn.113.082024. Epub 2014 Apr 2.
The results of human clinical trials investigating the effects of resveratrol on glucose control and insulin sensitivity are inconsistent.
We aimed to quantitatively evaluate the effects of resveratrol on glucose control and insulin sensitivity.
We performed a strategic literature search of PubMed, Embase, MEDLINE, and the Cochrane Library (updated to March 2014) for randomized controlled trials that estimated the effects of resveratrol on glucose control and insulin sensitivity. Study quality was assessed by using the Jadad scale. Weighted mean differences were calculated for net changes in glycemic measures by using fixed-effects or random-effects models. We performed prespecified subgroup and sensitivity analyses to evaluate potential heterogeneity. Meta-regression analyses were conducted to investigate dose effects of resveratrol on fasting glucose and insulin concentrations in nondiabetic subjects.
Eleven studies comprising a total of 388 subjects were included in this meta-analysis. Resveratrol consumption significantly reduced fasting glucose, insulin, glycated hemoglobin, and insulin resistance (measured by using the homeostatic model assessment) levels in participants with diabetes. No significant effect of resveratrol on glycemic measures of nondiabetic participants was found in the meta-analysis. Subgroup and sensitivity analyses indicated that the pooled effects of resveratrol on fasting glucose and insulin concentrations in nondiabetic participants were not affected by body mass index, study design, resveratrol dose, study duration, or Jadad score.
Resveratrol significantly improves glucose control and insulin sensitivity in persons with diabetes but does not affect glycemic measures in nondiabetic persons. Additional high-quality studies are needed to further evaluate the potential benefits of resveratrol in humans.
关于白藜芦醇对血糖控制和胰岛素敏感性影响的人体临床试验结果并不一致。
我们旨在定量评估白藜芦醇对血糖控制和胰岛素敏感性的影响。
我们对PubMed、Embase、MEDLINE和Cochrane图书馆（更新至2014年3月）进行了策略性文献检索，以查找估计白藜芦醇对血糖控制和胰岛素敏感性影响的随机对照试验。使用Jadad量表评估研究质量。采用固定效应或随机效应模型计算血糖指标净变化的加权平均差异。我们进行了预先设定的亚组分析和敏感性分析，以评估潜在的异质性。进行Meta回归分析，以研究白藜芦醇对非糖尿病受试者空腹血糖和胰岛素浓度的剂量效应。
本Meta分析纳入了11项研究，共388名受试者。食用白藜芦醇可显著降低糖尿病参与者的空腹血糖、胰岛素、糖化血红蛋白和胰岛素抵抗（通过稳态模型评估测量）水平。Meta分析未发现白藜芦醇对非糖尿病参与者的血糖指标有显著影响。亚组分析和敏感性分析表明，白藜芦醇对非糖尿病参与者空腹血糖和胰岛素浓度的合并效应不受体重指数、研究设计、白藜芦醇剂量、研究持续时间或Jadad评分的影响。
白藜芦醇可显著改善糖尿病患者的血糖控制和胰岛素敏感性，但对非糖尿病患者的血糖指标无影响。需要更多高质量的研究来进一步评估白藜芦醇对人类的潜在益处。
